MilliporeSigma Unveils AIDDISON™: Pioneering AI-Driven Drug Discovery and Synthesis Platform

Bridging virtual design and real-world manufacturing, MilliporeSigma's AIDDISON™ software revolutionizes the drug discovery process, offering a seamless, AI-powered route from molecule identification to synthesis.

by | Mar 18, 2024


MilliporeSigma has launched AIDDISON™, the first-of-its-kind software-as-a-service platform that integrates drug discovery with synthesis, leveraging generative AI, machine learning, and computer-aided design. This innovative platform is designed to significantly accelerate the drug development process by virtually screening over 60 billion chemical targets to identify promising drug candidates with optimal properties such as non-toxicity, solubility, and stability. AIDDISON™, integrating with Synthia™ retrosynthesis software, streamlines the path to synthesizing these candidates, aiming to make drug manufacturing safer, more cost-effective, and higher-yield. With drug discovery’s current lengthy timelines and high costs, AIDDISON™ emerges as a game-changer, poised to increase the success rate of new therapies reaching the market by optimizing the selection and synthesis process, promising significant savings in time and resources.

Key Takeaways

  • AIDDISON™ is a cutting-edge platform combining AI, machine learning, and computer-aided drug design, launched by MilliporeSigma.
  • It can screen over 60 billion chemical compounds, identifying those with key drug-like properties and proposing efficient synthesis routes.
  • The platform integrates with Synthia™ retrosynthesis API, offering recommendations for chemicals, reagents, and building blocks for drug synthesis.
  • Aimed at reducing the drug discovery and development process, which currently averages over 10 years and costs more than US$2 billion.
  • AIDDISON™ holds the potential to transform the pharmaceutical industry by increasing the success rate of new drugs and generating significant cost and time savings.

Key Quote

Karen Madden, CTO of Merck’s Life Science business sector, emphasized the platform’s impact, stating, “Our platform enables any laboratory to count on generative AI to identify the most suitable drug-like candidates in a vast chemical space. This helps ensure the optimal chemical synthesis route for development of a target molecule in the most sustainable way possible.” She highlighted the critical need for innovation in drug discovery, with the ultimate goal of delivering new therapies to patients more efficiently and sustainably.

Read the MilliporeSigma press release.

Millipore Sigma Logo

Related Content


Editor's Choice